CD274 and neoplasm: High levels of tumor-infiltrating lymphocytes (TILs), a high tumor mutational burden, and increased expression of PD-L1 render TNBC patients susceptible to immune checkpoint inhibitor (ICI) therapies, mainly PD-1- or PD-L1-directed immune modulations [20,21,22,23].